Premium
Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sG alectin‐1, sCD 163 and sCD 30 with TARC
Author(s) -
Plattel Wouter J.,
Alsada Zainab N. D.,
Imhoff Gustaaf W.,
Diepstra Arjan,
Berg Anke,
Visser Lydia
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14317
Subject(s) - medicine , lymphoma , chemokine , immunology , cd30 , ccl17 , gastroenterology , chemistry , cancer research , receptor , chemokine receptor
Summary Soluble Galectin‐1 ( sG al‐1, also termed LGALS 1), soluble CD 163 ( sCD 163) and soluble CD 30 ( sCD 30) have been reported to be elevated in plasma or serum of patients with classical Hodgkin lymphoma ( cHL ). We aimed to determine the clinical utility of these biomarkers for evaluation of treatment response compared to thymus and activation regulated chemokine ( TARC , also termed CCL 17). Plasma or serum samples were prospectively collected among 103 newly diagnosed cHL patients before and after treatment. Levels of sG al‐1, sCD 163, sCD 30 and TARC were correlated with disease characteristics and clinical treatment response. Elevated plasma levels of sG al‐1, sCD 163, sCD 30 and TARC were found in 67%, 21%, 91% and 93% of cHL patients respectively. Mean plasma levels of sG al‐1 and sCD 30 decreased after treatment but sCD 163 did not decrease after treatment. There was no correlation with change of these markers and clinical treatment response in individual patients. TARC levels strongly correlated with disease characteristics and metabolic volume. TARC remained high in 6 out of 7 non‐responsive patients and dramatically decreased in 95 out of 96 responsive patients. In summary, elevated pre‐treatment levels of sG al‐1, sCD 163, sCD 30 and TARC can be found in patients with cHL . However, only plasma TARC accurately reflects disease activity and correlates with clinical treatment response.